Whilst over half of countries with IV drug use have some form of harm reduction programmes, the total spend in low and middle income countries on harm reduction totals only $160m. Much work remains to be done.
People who inject drugs are a notable subset of HIV/AIDS patients worldwide. If HIV/AIDS is to be effectively tackled by 2030, IV drug harm reduction must not be sidelined, allowing users to slip through the net.
Data from 146 countries show some countries have achieved an important decline in new HIV infections, but many have not made measurable progress, and yet others have experienced worrying increases in new HIV infections.